Stockreport

CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

Cellectar Biosciences, Inc.  (CLRB) 
Last cellectar biosciences, inc. earnings: 11/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.cellectar.com
PDF Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to [Read more]